Published in J Exp Med on March 01, 1996
Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med (1998) 3.03
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol (2004) 2.28
Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc Natl Acad Sci U S A (2006) 1.91
CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol (2005) 1.49
The Epstein-Barr virus and its association with human cancers. Mol Pathol (1999) 1.26
Antigen kinetics determines immune reactivity. Proc Natl Acad Sci U S A (2008) 1.17
Noncompetitive expansion of cytotoxic T lymphocytes specific for different antigens during bacterial infection. Infect Immun (1999) 1.13
Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J Exp Med (1997) 1.09
Functional avidity: a measure to predict the efficacy of effector T cells? Clin Dev Immunol (2012) 1.01
T-cell memory: lessons from Epstein-Barr virus infection in man. Philos Trans R Soc Lond B Biol Sci (2000) 0.92
Gamma interferon and perforin control the strength, but not the hierarchy, of immunodominance of an antiviral CD8+ T cell response. J Virol (2011) 0.88
Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Springer Semin Immunopathol (1998) 0.85
Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome. PLoS One (2015) 0.85
Professional antigen presenting cells in human herpesvirus 8 infection. Front Immunol (2013) 0.84
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J Immunol (2012) 0.83
Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations. Am J Pathol (1999) 0.82
The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes. Int J Mass Spectrom (2007) 0.82
Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. J Virol (2012) 0.82
The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines. J Virol (2003) 0.81
Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2005) 0.80
A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype. Immunogenetics (2005) 0.79
Potentiation of T Cell Stimulatory Activity by Chemical Fixation of a Weak Peptide-MHC Complex. Mol Cells (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell (1978) 14.82
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A (1973) 12.70
Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol (1994) 8.16
Identification of self peptides bound to purified HLA-B27. Nature (1991) 4.88
Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol (1981) 4.27
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J (1986) 3.78
Assembly of MHC class I molecules analyzed in vitro. Cell (1990) 3.77
Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science (1993) 3.06
Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med (1994) 2.81
Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med (1991) 2.48
TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell (1993) 2.43
Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature (1990) 2.40
A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell (1992) 2.34
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med (1994) 2.04
Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell. Nature (1994) 2.02
T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol (1984) 2.01
Mechanisms influencing the immunodominance of T cell determinants. J Exp Med (1988) 1.91
Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol (1994) 1.90
Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides. J Immunol (1994) 1.85
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol (1993) 1.77
Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med (1994) 1.74
Peptide translocation by variants of the transporter associated with antigen processing. Science (1993) 1.71
An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. Hum Immunol (1986) 1.67
The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J Exp Med (1993) 1.65
Standards for total serum protein assays--a collaborative study. Clin Chem (1975) 1.65
A ubiquitous protein is the source of naturally occurring peptides that are recognized by a CD8+ T-cell clone. Proc Natl Acad Sci U S A (1993) 1.63
Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet (1980) 1.60
Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity (1995) 1.59
Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci U S A (1986) 1.38
Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res (1991) 1.36
An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc Natl Acad Sci U S A (1993) 1.30
Immunodominance in T lymphocyte recognition. Immunol Lett (1988) 1.12
Differential binding of a minor histocompatibility antigen peptide to H-2 class I molecules correlates with immune responsiveness. J Immunol (1993) 0.84
MHC class I-restricted antigen processing--lessons from natural ligands. Chem Immunol (1993) 0.83
Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol (2000) 5.14
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A (1997) 3.31
HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science (1993) 2.28
T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med (1994) 2.04
A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med (1998) 1.96
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol (1993) 1.77
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int J Cancer (1989) 1.74
Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med (1994) 1.66
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer (1987) 1.48
Disappearance of the NK effect after explantation of lymphocytes and generation of similar nonspecific cytotoxicity correlated to the level of blastogenesis in activated cultures. J Immunol (1980) 1.47
Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci U S A (1986) 1.38
An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc Natl Acad Sci U S A (1993) 1.30
Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci U S A (1992) 1.28
Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene (2009) 1.27
TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol (2000) 1.26
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer (1994) 1.20
Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma. Oncogene (2007) 1.16
c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol (2001) 1.13
Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. Cell Immunol (1983) 1.11
Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J Exp Med (1997) 1.09
Effect of interferon-alpha 1 from E. coli on some cell functions. Science (1980) 1.08
Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. Clin Immunol Immunopathol (1984) 1.05
Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer (1987) 1.03
The herpes simplex virus-1 Us3 protein kinase blocks CD8T cell lysis by preventing the cleavage of Bid by granzyme B. Cell Death Differ (2003) 1.03
Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor. J Exp Med (1982) 1.02
Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. Int J Cancer (1996) 1.02
The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J Immunol (1998) 1.01
Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res (2001) 1.01
The epstein-Barr-virus-encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. Int J Cancer (1991) 1.01
Synthesis of the 3'-half molecule of yeast alanine tRNA. Sci Sin B (1983) 1.01
The Epstein-Barr virus nuclear antigen-1 promotes telomere dysfunction via induction of oxidative stress. Leukemia (2011) 1.00
Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci U S A (2000) 1.00
T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis. Cancer Res (1981) 1.00
T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv (1992) 0.98
Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype. Virology (1993) 0.97
B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids. J Gen Virol (1991) 0.97
Host cell-dependent regulation of growth transformation-associated Epstein-Barr virus antigens in somatic cell hybrids. J Virol (1989) 0.96
Epstein-Barr virus (EBV)-specific cell-mediated and humoral immune responses in ataxia-telangectasia patients. J Clin Immunol (1984) 0.96
Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J Virol (1990) 0.95
Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer (1994) 0.94
Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus. Oncogene (2013) 0.92
Interleukin-10 abrogates the inhibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood (1998) 0.91
The ubiquitin-specific protease USP25 interacts with three sarcomeric proteins. Cell Mol Life Sci (2006) 0.90
Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes. J Immunol (1997) 0.90
Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells. Int Immunol (1992) 0.90
Parasympathetic cerebrovascular innervation: an anterograde tracing from the sphenopalatine ganglion in the rat. Neurosurgery (1993) 0.90
Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells. Int J Cancer (1991) 0.90
Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. J Immunol (1998) 0.89
Human T cell growth factor (TCGF) produced by repeated stimulation of non-adherent human lymphocytes. J Immunol Methods (1982) 0.89
Highly effective removal of heavy metals by polymer-based zirconium phosphate: a case study of lead ion. J Colloid Interface Sci (2007) 0.88
Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells. Int J Cancer (2000) 0.88
Avoiding proteasomal processing: the case of EBNA1. Curr Top Microbiol Immunol (2002) 0.88
Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob Agents Chemother (2001) 0.88
Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction. Eur J Immunol (1987) 0.87
High-resolution one-dimensional isoelectric focusing of mouse MHC class I antigens. Identification of natural and experimentally induced class I antigens. Immunogenetics (1990) 0.87
Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: a consequence of immune surveillance or a phenotypic vestige of the progenitor cells? Int J Cancer (1988) 0.87
Interferon suppresses antigen- and mitogen-induced leukocyte migration inhibition. Nature (1980) 0.87
Cellular immune defects to Epstein-Barr virus-determined antigens in young males. Cancer Res (1981) 0.87
cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. FEBS Lett (2001) 0.86
The pathogenesis of chyluria: retroperitoneal lymphangiectasis. Acta Acad Med Wuhan (1983) 0.86
Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogeneic mixed lymphocyte cultures. Eur J Immunol (1990) 0.86
Paired Epstein-Barr virus (EBV)-negative and EBV-converted Burkitt lymphoma lines: stimulatory capacity in allogeneic mixed lymphocyte cultures. Int J Cancer (1987) 0.85
B cell activation by the nontransforming P3HR-1 substrain of the Epstein-Barr virus (EBV). Eur J Immunol (1986) 0.84
High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes. FEBS Lett (1998) 0.84
Target selectivity of interferon-induced human killer lymphocytes related to their Fc receptor expression. Proc Natl Acad Sci U S A (1980) 0.84
Fabp3 inhibits proliferation and promotes apoptosis of embryonic myocardial cells. Cell Biochem Biophys (2011) 0.84
Effect of different Epstein-Barr virus-determined antigens (EBNA, EA, and VCA) on the leukocyte migration of healthy donors and patients with infectious mononucleosis and certain immunodeficiencies. Clin Immunol Immunopathol (1982) 0.84
Effect of interleukin-7 on the in vitro development and maturation of monocyte derived human dendritic cells. Scand J Immunol (2000) 0.83
Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones. Cell Immunol (1986) 0.83
A single specific amino acid residue in peptide antigens is sufficient to activate memory CTL: potential role of cross-reactive peptides in memory T cell maintenance. J Immunol (1999) 0.83
Solvent exposed side chains of peptides bound to HLA A*1101 have similar effects on the reactivity of alloantibodies and specific TCR. Int Immunol (1996) 0.83
Different programs of activation-induced cell death are triggered in mature activated CTL by immunogenic and partially agonistic peptide ligands. J Immunol (2001) 0.83
Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers. Cell Immunol (1984) 0.83
Pharmacological disintegration of lipid rafts decreases specific tetramer binding and disrupts the CD3 complex and CD8 heterodimer in human cytotoxic T lymphocytes. Scand J Immunol (2003) 0.82
Lysis of tumor biopsy cells by blood lymphocyte subsets of various densities. Autologous and allogeneic studies. Int J Cancer (1984) 0.82
Threshold of transmission of Brugia malayi by Anopheles sinensis. J Trop Med Hyg (1991) 0.82
A partially agonistic peptide acts as a selective inducer of apoptosis in CD8+ CTLs. J Immunol (1999) 0.81
Random coil conformation of a Gly/Ala-rich insert in IkappaB alpha excludes structural stabilization as the mechanism for protection against proteasomal degradation. FEBS Lett (1998) 0.81
T-cell-mediated inhibition of EBV-induced B-cell transformation: recognition of virus particles. Int J Cancer (1988) 0.81
Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. Int J Cancer (1992) 0.81
Transformation-associated Epstein-Barr virus antigens as targets for immune attack. Ann N Y Acad Sci (1993) 0.80
Antigen processing and presentation by EBV-carrying cell lines: cell-phenotype dependence and influence of the EBV-encoded LMP1. Int J Cancer (1993) 0.80
Effect of anchor residue modifications on the stability of HLA-A11/peptide complexes. Biochem Biophys Res Commun (1995) 0.80
Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides. Clin Exp Immunol (1996) 0.80
Cell-mediated immune reactions in three patients with malignant lymphoproliferative diseases in remission and abnormally high Epstein-Barr virus antibody titers. Cancer Res (1981) 0.80
Mechanisms of allele-selective down-regulation of HLA class I in Burkitt's lymphoma. Int J Cancer (1995) 0.80